nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-1-82-88nnp-1754Research ArticleREVIEWSОБЗОРЫImpact of different classes of antidepressants on sleep and wakefulness regulation in depressionВлияние антидепрессантов разных классов на регуляцию процессов сна и бодрствования при депрессииhttps://orcid.org/0000-0002-7619-1179УсовГ. М.UsovG. M.

644099, Омск, ул. Ленина, 12

12, Lenin St., Omsk 644099

usovgm@list.ruhttps://orcid.org/0000-0002-9330-4438КоломыцевД. Ю.KolomytsevD. Yu.

644099, Омск, ул. Ленина, 12

12, Lenin St., Omsk 644099

https://orcid.org/0000-0003-0251-5545ЛомиашвилиЛ. М.LomiashviliL. M.

644099, Омск, ул. Ленина, 12

12, Lenin St., Omsk 644099

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical University, Ministry of Health of RussiaRussian Federation2022260220221418288Copyright © Usov G.M., Kolomytsev D.Y., Lomiashvili L.M., 20222022Усов Г.М., Коломыцев Д.Ю., Ломиашвили Л.М.Usov G.M., Kolomytsev D.Y., Lomiashvili L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1754

Sleep disturbances are common in patients with mental disorders. Sleep disturbances, in particular insomnia, are widespread in depression. Depressed patients have a lot of sleep complaints that are often confirmed by polysomnography. Most antidepressants impair sleep, so drugs that help to restore sleep are of particular value in clinical practice. Agomelatine (valdoxan) rapidly improves sleep in depressed patients by making it easier to fall asleep, increasing total sleep time, duration of rapid eye movement (REM), and slow-wave sleep (SWS), and improving functioning during the day. 

Проблемы со сном широко распространены среди пациентов, страдающих психическими расстройствами. Нарушения сна, прежде всего инсомния, особенно часто встречаются при депрессии. Пациенты с депрессией предъявляют разнообразные жалобы на расстройства сна, которые часто подтверждаются при полисомнографическом исследовании. Большинство антидепрессантов ухудшают сон, поэтому препараты, способствующие его восстановлению, представляют особую ценность для клинической практики. Агомелатин (вальдоксан) обладает способностью быстро улучшать ночной сон у пациентов с депрессией, что проявляется в облегчении засыпания, увеличении общей продолжительности сна, длительности быстроволнового (REM) и медленноволнового (SWS) сна, а также улучшении дневного функционирования. 

депрессиярасстройства снаантидепрессантыагомелатинdepressionsleep disordersantidepressantsagomelatineReferencesAmerican Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). doi: 10.1176/appi.books.9780890425596American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). doi: 10.1176/appi.books.9780890425596Дмитриева ТБ, Голланд ВБ, Казаковцева БА, редакторы. Психические расстройства и расстройства поведения (F00–F99). Класс V МКБ-10, адаптированный для использования в РФ. Москва: РИО ГНЦ ССП им. В.П. Сербского; 1998. 360 с.Dmitrieva TB, Holland VB, Kazakovtseva BA, editors. Psikhicheskiye rasstroystva i rasstroystva povedeniya (F00-F99). Klass V MKB-10, adaptirovannyy dlya ispol'zovaniya v RF [Mental and behavioral disorders (F00-F99). Class V ICD-10, adapted for use in the Russian Federation]. Moscow: RIO GNTs SSP im. V.P. Serbskiy; 1998. 360 p. (In Russ.).Wilson S, Nutt D. (2013-09). Sleep Disorders (Oxford Psychiatry Library). Oxford, UK: Oxford University Press; 2013. Available from: https://oxfordmedicine.com/view/10.1093/med/9780199674558.001.0001/med-9780199674558 (accessed 26.07.2021).Wilson S, Nutt D. (2013-09). Sleep Disorders (Oxford Psychiatry Library). Oxford, UK: Oxford University Press; 2013. Available from: https://oxfordmedicine.com/view/10.1093/med/9780199674558.001.0001/med-9780199674558 (accessed 26.07.2021).Полуэктов МГ. Расстройства сна в практике психиатра. Современная терапия психических расстройств. 2012;(4):11-6.Poluektov MG. Sleep disorders in psychiatric practice. Sovremennaya terapiya psikhicheskikh rasstroystv. 2012;(4):11-6 (In Russ.).Голенков АВ. Нарушения сна при психических расстройствах. Эффективная фармакотерапия. Неврология и психиатрия. Спецвыпуск «Сон и его расстройства». 2014;(2):22-9.Golenkov AV. Sleep disorders in mental disorders. effective pharmacotherapy. Nevrologiya i psikhiatriya. Spetsvypusk “Son i yego rasstroystva”. 2014;(2):22-9 (In Russ.).Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord. 2014;167:93-7. doi: 10.1016/j.jad.2014.05.060. Epub 2014 Jun 6.Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord. 2014;167:93-7. doi: 10.1016/j.jad.2014.05.060. Epub 2014 Jun 6.Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018 Sep;72(9):673-82. doi: 10.1111/pcn.12688. Epub 2018 Jul 4.Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018 Sep;72(9):673-82. doi: 10.1111/pcn.12688. Epub 2018 Jul 4.Hensch T, Wozniak D, Spada J, et al. Vulnerability to bipolar disorder is linked to sleep and sleepiness. Transl Psychiatry. 2019 Nov 11;9(1):294. doi: 10.1038/s41398-019-0632-1Hensch T, Wozniak D, Spada J, et al. Vulnerability to bipolar disorder is linked to sleep and sleepiness. Transl Psychiatry. 2019 Nov 11;9(1):294. doi: 10.1038/s41398-019-0632-1Cipriani G, Lucetti C, Danti S, et al. Sleep disturbances and dementia. Psychogeriatrics. 2015 Mar;15(1):65-74. doi: 10.1111/psyg.12069. Epub 2014 Dec 16.Cipriani G, Lucetti C, Danti S, et al. Sleep disturbances and dementia. Psychogeriatrics. 2015 Mar;15(1):65-74. doi: 10.1111/psyg.12069. Epub 2014 Dec 16.Wennberg AMV, Wu MN, Rosenberg PB, et al. Sleep Disturbance, Cognitive Decline, and Dementia: A Review. Semin Neurol. 2017 Aug;37(4):395-406. doi: 10.1055/s-0037-1604351. Epub 2017 Aug 24.Wennberg AMV, Wu MN, Rosenberg PB, et al. Sleep Disturbance, Cognitive Decline, and Dementia: A Review. Semin Neurol. 2017 Aug;37(4):395-406. doi: 10.1055/s-0037-1604351. Epub 2017 Aug 24.Cosgrave J, Wulff K, Gehrman P. Sleep, circadian rhythms, and schizophrenia: where we are and where we need to go. Curr Opin Psychiatry. 2018 May;31(3):176-82. doi: 10.1097/YCO.0000000000000419Cosgrave J, Wulff K, Gehrman P. Sleep, circadian rhythms, and schizophrenia: where we are and where we need to go. Curr Opin Psychiatry. 2018 May;31(3):176-82. doi: 10.1097/YCO.0000000000000419Ferrarelli F. Sleep disturbances in schizophrenia and psychosis. Schizophr Res. 2020 Jul;221:1-3. doi: 10.1016/j.schres.2020.05.022. Epub 2020 May 26.Ferrarelli F. Sleep disturbances in schizophrenia and psychosis. Schizophr Res. 2020 Jul;221:1-3. doi: 10.1016/j.schres.2020.05.022. Epub 2020 May 26.Li P, Gao L, Gaba A, et al. Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults. Lancet Healthy Longev. 2020 Dec;1(3):e96-e105. doi: 10.1016/s2666-7568(20)30015-5. Epub 2020 Nov 12.Li P, Gao L, Gaba A, et al. Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults. Lancet Healthy Longev. 2020 Dec;1(3):e96-e105. doi: 10.1016/s2666-7568(20)30015-5. Epub 2020 Nov 12.Левин ЯИ. Депрессия и сон. Психиатрия и психофармакотерапия. 2000;2(1):20-3.Levin YaI. Depression and sleep. Psikhiatriya i psikhofarmakoterapiya. 2000;2(1):20-3 (In Russ.).Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl. 2007;(433):104-15. doi: 10.1111/j.1600-0447.2007.00968.xArmitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl. 2007;(433):104-15. doi: 10.1111/j.1600-0447.2007.00968.xFang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019 Apr;23(4):2324-32. doi: 10.1111/jcmm.14170. Epub 2019 Feb 7.Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019 Apr;23(4):2324-32. doi: 10.1111/jcmm.14170. Epub 2019 Feb 7.Lacruz ME, Schmidt-Pokrzywniak A, Dragano N, et al. Depressive symptoms, life satisfaction and prevalence of sleep disturbances in the general population of Germany: results from the Heinz Nixdorf Recall study. BMJ Open. 2016 Jan 4;6(1):e007919. doi: 10.1136/bmjopen-2015-007919Lacruz ME, Schmidt-Pokrzywniak A, Dragano N, et al. Depressive symptoms, life satisfaction and prevalence of sleep disturbances in the general population of Germany: results from the Heinz Nixdorf Recall study. BMJ Open. 2016 Jan 4;6(1):e007919. doi: 10.1136/bmjopen-2015-007919Pandi-Perumal SR, Monti JM, Burman D, et al. Clarifying the role of sleep in depression: A narrative review. Psychiatry Res. 2020 Sep;291:113239. doi: 10.1016/j.psychres.2020.113239. Epub 2020 Jun 16.Pandi-Perumal SR, Monti JM, Burman D, et al. Clarifying the role of sleep in depression: A narrative review. Psychiatry Res. 2020 Sep;291:113239. doi: 10.1016/j.psychres.2020.113239. Epub 2020 Jun 16.Hawkins DR, Taub JM, van de Castle RL. Extended sleep (hypersomnia) in young depressed patients. Am J Psychiatry. 1985 Aug;142(8):905-10. doi: 10.1176/ajp.142.8.905Hawkins DR, Taub JM, van de Castle RL. Extended sleep (hypersomnia) in young depressed patients. Am J Psychiatry. 1985 Aug;142(8):905-10. doi: 10.1176/ajp.142.8.905Lopez R, Barateau L, Evangelista E, Dauvilliers Y. Depression and Hypersomnia: A Complex Association. Sleep Med Clin. 2017 Sep;12(3):395-405. doi: 10.1016/j.jsmc.2017.03.016. Epub 2017 May 26.Lopez R, Barateau L, Evangelista E, Dauvilliers Y. Depression and Hypersomnia: A Complex Association. Sleep Med Clin. 2017 Sep;12(3):395-405. doi: 10.1016/j.jsmc.2017.03.016. Epub 2017 May 26.Lojko D, Rybakowski JK. Atypical depression: current perspectives. Neuropsychiatr Dis Treat. 2017 Sep 20;13:2447-56. doi: 10.2147/NDT.S147317. eCollection 2017.Lojko D, Rybakowski JK. Atypical depression: current perspectives. Neuropsychiatr Dis Treat. 2017 Sep 20;13:2447-56. doi: 10.2147/NDT.S147317. eCollection 2017.Grigolon RB, Trevizol AP, Cerqueira RO, et al. Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. J Affect Disord. 2019 Mar 1;246:659-66. doi: 10.1016/j.jad.2018.12.030. Epub 2018 Dec 18.Grigolon RB, Trevizol AP, Cerqueira RO, et al. Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. J Affect Disord. 2019 Mar 1;246:659-66. doi: 10.1016/j.jad.2018.12.030. Epub 2018 Dec 18.Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-81. doi: 10.31887/DCNS.2008.10.4/plfranzenFranzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-81. doi: 10.31887/DCNS.2008.10.4/plfranzenMurphy MJ, Peterson MJ. Sleep Disturbances in Depression. Sleep Med Clin. 2015 Mar;10(1):17-23. doi: 10.1016/j.jsmc.2014.11.009. Epub 2014 Dec 12.Murphy MJ, Peterson MJ. Sleep Disturbances in Depression. Sleep Med Clin. 2015 Mar;10(1):17-23. doi: 10.1016/j.jsmc.2014.11.009. Epub 2014 Dec 12.Steiger A, Pawlowski M, Kimura M. Sleep electroencephalography as a biomarker in depression. Chrono Physiol Ther. 2015;5:15- 25 doi: 10.2147/CPT.S41760Steiger A, Pawlowski M, Kimura M. Sleep electroencephalography as a biomarker in depression. Chrono Physiol Ther. 2015;5:15- 25 doi: 10.2147/CPT.S41760Kupfer DJ. The application of EEG sleep in the treatment of depression. In: Mendlewicz J, van Praag HM, editors. Advances in Biological Psychiatry. Basel, Switzerland: S. Karger; 1981. P. 87-93.Kupfer DJ. The application of EEG sleep in the treatment of depression. In: Mendlewicz J, van Praag HM, editors. Advances in Biological Psychiatry. Basel, Switzerland: S. Karger; 1981. P. 87-93.Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. Cambridge University Press; 2013.Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. Cambridge University Press; 2013.Stahl SM. Stahl's essential psychopharmacology: Prescriber's guide. 5th ed. Cambridge University Press; 2014.Stahl SM. Stahl's essential psychopharmacology: Prescriber's guide. 5th ed. Cambridge University Press; 2014.Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-47. doi: 10.2165/00003495-200565070-00003Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-47. doi: 10.2165/00003495-200565070-00003Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005 Dec;20(8):533-59. doi: 10.1002/hup.726Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005 Dec;20(8):533-59. doi: 10.1002/hup.726Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017 Aug 9;19(9):63. doi: 10.1007/s11920-017-0816-4Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017 Aug 9;19(9):63. doi: 10.1007/s11920-017-0816-4Мосолов СН. Тревожные и депрессивные расстройства: коморбидность и терапия. Москва: Артинфопаблишинг; 2007. C. 29-30.Mosolov SN. Trevozhnyye i depressivnyye rasstroystva: komorbidnost' i terapiya [Anxiety and depressive disorders: comorbidity and therapy]. Moscow: Artinfopublishing; 2007. P. 29- 30 (In Russ.).Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714-200104000-00008Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714-200104000-00008Baldwin DS, et al. Poster presented at the 13th International Forum on Mood and Anxiety Disorders (IFMAD), November 20-22, 2013. Monaco; 2013.Baldwin DS, et al. Poster presented at the 13th International Forum on Mood and Anxiety Disorders (IFMAD), November 20-22, 2013. Monaco; 2013.Sunami E, Usuda K, Nishiyama Y, et al. A Preliminary Study of Fluvoxamine Maleate on Depressive State and Serum Melatonin Levels in Patients after Cerebral Infarction. Intern Med. 2012;51(10):1187-93. doi: 10.2169/internalmedicine.51.6699. Epub 2012 May 15.Sunami E, Usuda K, Nishiyama Y, et al. A Preliminary Study of Fluvoxamine Maleate on Depressive State and Serum Melatonin Levels in Patients after Cerebral Infarction. Intern Med. 2012;51(10):1187-93. doi: 10.2169/internalmedicine.51.6699. Epub 2012 May 15.Смулевич АБ, Ильина НА, Читлова ВВ. Место флувоксамина в лечении депрессии в России: открытое неконтролируемое рандомизированное многоцентровое обсервационное исследование. Психиатрия и психофармакотерапия. 2016;18(1):4-10.Smulevich AB, Ilyina NA, Chitlova VV. Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label Uncontrolled and Randomized Multicenter Observational Study. Psihiatriya i psihofarmakoterapiya. 2016;18(1):4-10 (In Russ.).Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients with Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi: 10.2147/NSS.S220947. eCollection 2019.Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients with Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi: 10.2147/NSS.S220947. eCollection 2019.Волель БА. Вальдоксан (агомелатин): инновационный механизм действия. Психиатрия и психофармакотерапия. 2008;10(3):35-9.Volel BA. Valdoxan (agomelatine): an innovative mechanism of action. Psihiatriya i psihofarmakoterapiya. 2008;10(3):35-9 (In Russ.).Иванов СВ. Агомелатин (вальдоксан) – первый мелатонинергический антидепрессант. В кн.: Мосолов СН, редактор. Хронобиологическая теория аффективных расстройств. Москва: АВАНПОРТ; 2014. С. 218-65.Ivanov SV. Agomelatine (Valdoxan) is the first melatonergic antidepressant. In: Mosolov SN, editor. Khronobiologicheskaya teoriya affektivnykh rasstroystv [Chronobiological theory of affective disorders]. Moscow: AVANPORT; 2014. P. 218-65 (In Russ.).Медведев ВЭ, Ретюнский КЮ, Овчинников АА и др. Различия в оценке тяжести депрессии врачами и пациентами в процессе комбинированной терапии агомелатином (мультицентровое исследование «ЭМОЦИЯ»). Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(11):26-34. doi: 10.17116/jnevro201611611126-34Medvedev V, Retyunskiy KYu, Ovchinnikov AA, et al. The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study “EMOTSIA”). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(11):26-34. doi: 10.17116/jnevro201611611126-34 (In Russ.).Medvedev V, Retyunskii K, Ovchinnikov A, et al. Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial). Neurosci Behav Physiol. 2018;48:367-76. doi: 10.1007/s11055-018-0572-xMedvedev V, Retyunskii K, Ovchinnikov A, et al. Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial). Neurosci Behav Physiol. 2018;48:367-76. doi: 10.1007/s11055-018-0572-xQuera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6. doi: 10.1017/S1461145707007754. Epub 2007 May 4.Quera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6. doi: 10.1017/S1461145707007754. Epub 2007 May 4.Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi: 10.1097/YIC.0b013e328349b117Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi: 10.1097/YIC.0b013e328349b117Иванов СВ. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС»). Психиатрия и психофармакотерапия. 2009;11(6):14-7.Ivanov SV. Valdoxan (agomelatine) in the treatment of moderate and severe non-psychotic depression in outpatient and hospital practice (results of the Russian multicenter study “CHRONOS”). Psihiatriya i psihofarmakoterapiya. 2009;11(6):14-7 (In Russ.).Смулевич АБ, Андрющенко АВ, Бескова ДА. Терапия непсихотических депрессий антидепрессантом агомелатином (Вальдоксан): результаты наблюдательного многоцентрового исследования «РИТМ». Психиатрия и психофармакотерапия. 2010;12(4):4-11.Smulevich AB, Andryushchenko AV, Beskova DA. Treatment of non-psychotic depression with the antidepressant agomelatine (Valdoxan): results of the RITM observational multicenter study. Psihiatriya i psihofarmakoterapiya. 2010;12(4):4-11 (In Russ.).Полуэктов МГ, Левин ЯИ. Результаты российского мультицентрового открытого обсервационного несравнительного исследования эффективности и безопасности вальдоксана (агомелатин) при лечении пациентов с большим депрессивным расстройством и нарушениями сна (исследование ВИВАЛЬДИ). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(12):39-44.Poluektov MG, Levin YaI. The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(12):39-44 (In Russ.).

The authors declare that there are no conflicts of interest present.